UNSPSC 51352010: Norgestimate

This classification denotes a therapeutic progestin with the molecular formula C23H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C291HFX4DY, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17-alpha)- but generally known as norgestimate, which bears US NIH Compound Identifier 6540478. European Medicines Agency schedules Norgestimate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09369MIG.

UNSPSC 51352010 Norgestimate, a Commodity code, encompasses generic pharmaceutical products sourced through state and local cooperative purchasing agreements. State and local governments procure norgestimate and related generic multi-source pharmaceuticals through master agreements established via cooperative purchasing vehicles, typically administered by state procurement offices on behalf of multiple participating jurisdictions. The work involves pharmaceutical manufacturers supplying products to authorized wholesalers at negotiated pricing, with vendors required to maintain FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance. Purchasing bodies include state health departments, local government facilities, and participating state and local institutions within cooperative alliances; the issuing structure favors multi-state cooperative agreements rather than individual jurisdiction procurement.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The procurement covers participating jurisdictions in Minnesota and Oregon and requires vendors to distribute products through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must provide detailed product information including National Drug Codes (NDC), SKUs, UPCs, and packaging configurations, with all products available by May 15, 2026 and resulting contracts effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent), with the remainder weighted across fixed pricing, EDI capability, administrative fee compliance, and administrative data format requirements. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers and carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. The contract term runs two years for new responders with optional extensions at MMCAP's discretion.